CATEGORIES: General SLE
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
To Learn More Contact:
Contact: UCB Cares +1844599 ext 2273 UCBCares@ucb.com
ClinicalTrials.gov Identifer: NCT04294667